 Connection
Thomas Flaig to Androgen Antagonists
This is a "connection" page, showing publications Thomas Flaig has written about Androgen Antagonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.408 |
|
|
|
-
Boxley PJ, Smith DE, Gao D, Kessler ER, Echalier B, Bernard B, Ormond DR, Lam ET, Kavanagh BD, Flaig TW. Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort. Clin Genitourin Cancer. 2021 06; 19(3):217-222.e1.
Score: 0.610
-
Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol. 2017 Nov 09; 3(11):e170231.
Score: 0.503
-
Flaig TW, Glodé LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother. 2008 Nov; 9(16):2829-41.
Score: 0.269
-
Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 10; 78(4):603-614.
Score: 0.149
-
Castro-Alonso FJ, Dominguez-Pineda J, Rosales-Sotomayor G, Flaig TW, Bourlon MT. Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors. Oncology (Williston Park). 2018 05 15; 32(5):243-6.
Score: 0.130
-
Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 05 20; 36(15):1498-1504.
Score: 0.129
-
Kessler ER, Flaig TW. Optimal management of recurrent prostate cancer in older patients. Drugs Aging. 2012 Nov; 29(11):871-83.
Score: 0.089
-
Lam ET, Flaig TW. Prostate cancer: celecoxib trampled in the STAMPEDE trial. Nat Rev Urol. 2012 May 29; 9(7):358-60.
Score: 0.086
-
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26; 364(21):1995-2005.
Score: 0.080
-
Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20; 29(15):2040-5.
Score: 0.080
-
Sumey C, Flaig TW. Adjuvant medical therapy for prostate cancer. Expert Opin Pharmacother. 2011 Jan; 12(1):73-84.
Score: 0.078
-
O'Bryant CL, Flaig TW, Utz KJ. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy. 2008 Aug; 28(8):1071-5.
Score: 0.066
-
Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glodé LM. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer. 2006 Jul 15; 107(2):266-74.
Score: 0.057
-
Eule CJ, Kuna EM, Robin TP, Gershman B, Flaig TW, Kim SP. Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database. Urol Oncol. 2024 12; 42(12):447.e17-447.e24.
Score: 0.050
-
Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 08 20; 34(24):2835-42.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|